Merck’s Priority Review Cancer Drug Adds To Undervalued Growth Story

U.S. FDA accepts and grants Priority Review for the Biologics License Application for ifinatamab deruxtecan. The application ...

MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer

Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above ...

Mom Who Never Smoked Given 12 Years to Live After Stage 4 Lung Cancer Diagnosis. 6 Years Later, 'There Is No Cancer'

Leah Phillips, a Kentucky mom of three, said she was initially told her symptoms were due to a cold, allergies or anxiety ...

A lung cancer that changes its identity may be hiding in plain sight

A new study co-led by the Institute for Systems Biology (ISB) shows that some lung cancers can change identity as they evolve ...

Cancer's hidden switch may sit in the cell membrane, forcing growth receptors into permanent overdrive

Cells are enveloped by a lipid membrane that gives them structure and provides a barrier between the cell and its environment ...

Non-Smoker with Stage 4 Lung Cancer Was Given a Year to Live. That Was 7 Years Ago (Exclusive)

Dave Nitsche is planning to cycle 1,000 km in June as he strives to change "misconceptions" about living with cancer ...

Lung Cancer Research Foundation Grants Team Science Award Focused on Curing EGFR-Mutant Lung Cancers

The Lung Cancer Research Foundation (LCRF) announces the first recipients of its LCRF Team Science Award on Advancing Therapies Toward Curing EGFR Mutated Lung Cancers. The project, "A novel ...

Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England Journal of Medicine

This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn.Boehringer Ingelheim today announced that The New ...

Novel strategy enables protection against radiation therapy resistance in lung cancer

In a preclinical study published in Cancer Research, researchers from the University of Texas MD Anderson Cancer Center have ...
VTV

New milestone in lung cancer treatment: Achieving curative intent with targeted therapy and immunotherapy

AstraZeneca, in collaboration with the Vietnam Cancer Association, organized a scientific symposium titled "A new era in lung ...
Medscape

Scotland Clears New Option for EGFR Lung Cancer

The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.